Benitec Biopharma, Inc.

As of June 18, 2025, the trend is mildly bullish due to a bullish daily moving average and a mildly bullish weekly MACD, but mixed signals from the weekly KST and Dow Theory suggest a cautious approach.

Benitec Biopharma, Inc. is a clinical-stage biotechnology company focused on developing genetic medicines. As of March 2025, it has a market cap of $405.31 million and reported a net profit loss of $9 million.

As of Jun 18, Benitec Biopharma, Inc. has a market capitalization of 405.31 million, categorizing it as a Micro Cap company, with net sales of 0.00 million and a net profit of -26.49 million for the latest four quarters. As of June 2024, shareholder's funds were 47.25 million and total assets were 52.21 million.